Skip to main content
. Author manuscript; available in PMC: 2024 May 15.
Published in final edited form as: Circulation. 2023 Nov 30;149(1):e1–e156. doi: 10.1161/CIR.0000000000001193

Recommendations for Acute Rate Control

Referenced studies that support the recommendations are summarized in the Online Data Supplement.

COR LOE Recommendations
1 B-R 1. In patients with AF with rapid ventricular response who are hemodynamically stable, beta blockers or nondihydropyridine calcium channel blockers (verapamil, diltiazem; provided that EF >40%) are recommended for acute rate control (Figure 17).14
2a B-R 2. In patients with AF with rapid ventricular response in whom beta blockers and nondihydropyridine calcium channel blockers are ineffective or contraindicated, digoxin can be considered for acute rate control, either alone or in combination with the aforementioned agents.59
2a A 3. In patients with AF with rapid ventricular response, the addition of intravenous magnesium to standard rate-control measures is reasonable to achieve and maintain rate control.10,11
2b B-NR 4. In patients with AF with rapid ventricular response who are critically ill and/or in decompensated HF in whom beta blockers and nondihydropyridine calcium channel blockers are ineffective or contraindicated, intravenous amiodarone may be considered for acute rate control.*12,13
3: Harm B-NR 5. In patients with AF with rapid ventricular response and known moderate or severe LV systolic dysfunction with or without decompensated HF, intravenous nondihydropyridine calcium channel blockers should not be administered.14,15
*

Consider the risk of cardioversion and stroke when using amiodarone as a rate-control agent.